+ Follow OXFORD UNIVERSITY CLINICAL TRIAL SERVICE UNIT Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 636431
[Title] => Hearty news from MSD
[Summary] => A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo (p=0.0010).
[DatePublished] => 2010-12-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
)
)
OXFORD UNIVERSITY CLINICAL TRIAL SERVICE UNIT
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 636431
[Title] => Hearty news from MSD
[Summary] => A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo (p=0.0010).
[DatePublished] => 2010-12-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
)
)
abtest
December 7, 2010 - 12:00am